Catalysts for $LLY
77 tracked
Aug 5, 2026
earnings
ELI LILLY & Co earnings
ELI LILLY & Co
→
Apr 30, 2026
earnings
ELI LILLY & Co earnings
ELI LILLY & Co
→
Apr 1, 2026
approval
FOUNDAYO (ORFORGLIPRON CALCIUM) — FDA approval
orforglipron calcium
→
Mar 12, 2026
approval
TRULICITY (DULAGLUTIDE) — FDA approval
dulaglutide
→
Feb 25, 2026
approval
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Jan 20, 2026
approval
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Jan 20, 2026
approval
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Jan 7, 2026
approval
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Jan 7, 2026
approval
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Dec 19, 2025
approval
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Nov 20, 2025
approval
RETEVMO (SELPERCATINIB) — FDA approval
selpercatinib
→
Nov 20, 2025
approval
RETEVMO (SELPERCATINIB) — FDA approval
selpercatinib
→
Nov 20, 2025
approval
RETEVMO (SELPERCATINIB) — FDA approval
selpercatinib
→
Nov 20, 2025
approval
RETEVMO (SELPERCATINIB) — FDA approval
selpercatinib
→
Oct 28, 2025
approval
EBGLYSS (LEBRIKIZUMAB-LBKZ) — FDA approval
lebrikizumab
→
Oct 23, 2025
approval
OMVOH (MIRIKIZUMAB-MRKZ) — FDA approval
mirikizumab
→
Sep 25, 2025
approval
INLURIYO (IMLUNESTRANT TOSYLATE) — FDA approval
imlunestrant tosylate
→
Sep 25, 2025
approval
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Sep 25, 2025
approval
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
May 28, 2025
approval
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
May 28, 2025
approval
TRULICITY (DULAGLUTIDE) — FDA approval
dulaglutide
→
May 22, 2025
approval
EBGLYSS (LEBRIKIZUMAB-LBKZ) — FDA approval
lebrikizumab
→
Feb 7, 2025
approval
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Jan 15, 2025
approval
OMVOH (MIRIKIZUMAB-MRKZ) — FDA approval
mirikizumab
→
Jan 15, 2025
approval
OMVOH (MIRIKIZUMAB-MRKZ) — FDA approval
mirikizumab
→
Dec 20, 2024
approval
ZEPBOUND (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Dec 18, 2024
approval
RETEVMO (SELPERCATINIB) — FDA approval
selpercatinib
→
Dec 18, 2024
approval
RETEVMO (SELPERCATINIB) — FDA approval
selpercatinib
→
Nov 1, 2024
approval
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→
Nov 1, 2024
approval
MOUNJARO (TIRZEPATIDE) — FDA approval
ZEPBOUND
→